Used in research settings as a selective agonist for the GPR40 receptor, which is involved in insulin secretion pathways. Shows potential in studies related to type 2 diabetes due to its ability to enhance glucose-dependent insulin release from pancreatic beta cells. Investigated for its role in improving glycemic control without causing hypoglycemia, making it a candidate for developing new antidiabetic therapies. Also employed as a pharmacological tool to study GPR40 receptor function and signaling mechanisms in cellular and animal models.